title: Clinical assessment, platelet reactivity measurement or genetic testing after acute coronary syndrome? What benefits the patient?
authors.forename: Mirjam
authors.initials: M
authors.lastname: Keßler
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Rottbauer
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Koenig
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D004351:Drug Resistance / Q000235:genetics*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine